Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 671-680 of 3419 for cancer

Edit search filters
  1. Temsirolimus and Bevacizumab in Treating Patients with Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

    Rochester, MN, Jacksonville, FL, Scottsdale/Phoenix, AZ

  2. A Study to Evaluate Niraparib and TSR-042 in Patients with Germline or Somatic BRCA1/2 and PALB2-related Pancreatic Cancer

    Rochester, MN, Jacksonville, FL, Scottsdale/Phoenix, AZ

  3. Study Of Quemliclustat And Chemotherapy Versus Placebo And Chemotherapy In Patients With Metastatic Pancreatic Ductal Adenocarcinoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. A Study to Compare Administering Olaparib Concurrently With Radiotherapy vs. Radiotherapy Alone in Treating Patients With Inflammatory Breast Cancer

    La Crosse, WI, Eau Claire, WI, Rochester, MN

  5. Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

    Rochester, MN

  6. Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

    Rochester, MN, Scottsdale/Phoenix, AZ

  7. FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

    Rochester, MN

  8. PLX038 for the Treatment of Metastatic Ovarian, Peritoneal, and Fallopian Tube Cancers

    Rochester, MN

  9. Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Rochester, MN

  10. A Study to Evaluate Belinostat and Guadecitabine or ASTX727 to Treat Unresectable and Metastatic Conventional Chondrosarcoma

    Scottsdale/Phoenix, AZ, Rochester, MN, Jacksonville, FL

.

Mayo Clinic Footer